LixiPark (lixisenatide) trial results by Prof Olivier Rascol

We are delighted to share this recording, the 2nd of a series of 4, that one of the world's leading PD Charities, Cure Parkinson's, hosted recently in Central London.

The results of the Cure Parkinson's co-funded phase 2 clinical trial of lixisenatide (LixiPark study) were published in the New England Journal of Medicine. The researchers reported that the trial had met its primary outcome, indicating that lixisenatide may be able to delay the progression of motor symptoms in Parkinson’s. In this talk, Professor Olivier Rascol - one of the primary investigators - will be presenting and discussing the trial findings.

Lixisenatide belongs to a class of Type 2 diabetes drugs called GLP-1 receptor agonists. This is the second phase 2 clinical trial involving GLP-1 receptor agonists for Parkinson’s to have positive results, the first being the 2017 phase 2 trial of exenatide.

Read more about the LixiPark study on Cure Parkinson's website: https://cureparkinsons.org.uk/2024/04...

The study, sponsored by the Toulouse University Hospital, was co-funded by Cure Parkinson’s with Van Andel Institute (VAI; in Michigan, US), and the French Ministry of Health, with drug and placebo support from pharmaceutical company Sanofi.

DONATE TO FURTHER RESEARCH WITH CURE PARKINSON'S HERE:- https://cureparkinsons.org.uk/donate-...

⚠️ MEDICAL DISCLAIMER: This content is for informational and educational purposes only and is not intended as a substitute for professional medical advice. Always consult your physician or specialist regarding your Parkinson's treatment and care.

JOIN OUR COMMUNITY: Want more expert insights? Register for our webinars and updates at https://nosilverbullet4pd.com/